These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31848185)

  • 1. A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models.
    DaSilva JO; Yang K; Perez Bay AE; Andreev J; Ngoi P; Pyles E; Franklin MC; Dudgeon D; Rafique A; Dore A; Delfino FJ; Potocky TB; Babb R; Chen G; MacDonald D; Olson WC; Thurston G; Daly C
    Clin Cancer Res; 2020 Mar; 26(6):1408-1419. PubMed ID: 31848185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
    DaSilva JO; Yang K; Surriga O; Nittoli T; Kunz A; Franklin MC; Delfino FJ; Mao S; Zhao F; Giurleo JT; Kelly MP; Makonnen S; Hickey C; Krueger P; Foster R; Chen Z; Retter MW; Slim R; Young TM; Olson WC; Thurston G; Daly C
    Mol Cancer Ther; 2021 Oct; 20(10):1966-1976. PubMed ID: 34315762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.
    Godar M; Morello V; Sadi A; Hultberg A; De Jonge N; Basilico C; Hanssens V; Saunders M; Lambrecht BN; El Khattabi M; de Haard H; Michieli P; Blanchetot C
    Sci Rep; 2016 Aug; 6():31621. PubMed ID: 27546726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sym015: A Highly Efficacious Antibody Mixture against
    Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
    Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
    Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
    BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both
    Wang J; Anderson MG; Oleksijew A; Vaidya KS; Boghaert ER; Tucker L; Zhang Q; Han EK; Palma JP; Naumovski L; Reilly EB
    Clin Cancer Res; 2017 Feb; 23(4):992-1000. PubMed ID: 27573171
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.
    Yang Y; Mandiyan S; Robinson BS; McMahon G
    Cancer Res; 2016 Oct; 76(19):5788-5797. PubMed ID: 27550450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
    Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
    Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired Resistance to a MET Antibody
    Pollmann SE; Calvert VS; Rao S; Boca SM; Madhavan S; Horak ID; Kjaer A; Petricoin EF; Kragh M; Poulsen TT
    Mol Cancer Ther; 2018 Jun; 17(6):1259-1270. PubMed ID: 29545332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
    J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
    Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
    Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
    Park H; Kim D; Kim E; Sa JK; Lee HW; Yu S; Oh J; Kim SH; Yoon Y; Nam DH
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.
    Grandal MM; Havrylov S; Poulsen TT; Koefoed K; Dahlman A; Galler GR; Conrotto P; Collins S; Eriksen KW; Kaufman D; Woude GFV; Jacobsen HJ; Horak ID; Kragh M; Lantto J; Bouquin T; Park M; Pedersen MW
    Mol Cancer Ther; 2017 Dec; 16(12):2780-2791. PubMed ID: 28802255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
    Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
    Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
    Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
    Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
    Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.